Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-01-08
1999-02-16
Geist, Gary
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
5142248, 5142262, 514323, 514415, 514419, 514619, 514648, A61K 3144, A61K 31445, A61K 3140
Patent
active
058721274
ABSTRACT:
Disclosed are methods for treating a disorder to the immune system or an immunodeficiency state which comprise the steps of administering to a patient an effective amount of at least one serotonin agonist and at least one dopamine agonist, where the combination of the serotonin agonist and the dopamine agonist are present in an amount effective to treat the patient's condition, where administration of each of the agents is confined to the time of day during which the administration is capable of adjusting the prolactin profile of the patient to conform or to approach the standard human prolactin profile.
REFERENCES:
patent: 4310535 (1982-01-01), Pierpaoli
patent: 4665086 (1987-05-01), Short et al.
patent: 5028591 (1991-07-01), Edwards et al.
patent: 5145837 (1992-09-01), Feven et al.
patent: 5344832 (1994-09-01), Cincotta et al.
patent: 5519047 (1996-05-01), Shelby et al.
J. W. Holaday, "Neuroendocrine-. . . Medicine", Klin Wochenschr, vol. 69, Suppl. XXVI, pp. 13-19, 1991.
P.M. Reber, "Prolactin & Immunomodulation", American J. of Medicine, vol. 96(6), pp. 637-644, Dec. 1993.
Barnett et al., Postgraduate Med. J., 56:11-14, 1980.
Berczi, I. et al., Acta Endocrinologica, 98:506-513, 1980.
Berczi, I., Dev. Comp. Immunol., 13:329-341, 1989.
Bernton, E.S. et al., Science, 239:401-4, 1989, Jan.
Besedovsky, H.O. et al., J. Immunol., 135:750s-4s, 1985.
Blalock, J.E., Physiol. Rev., 69:1-32, 1989.
Blizhakov, J. Med. N.Y., 1980, 11(2/3):81-105.
Folomeev et al., Biological Abstracts, vol. 90, abstract No. 75731, Ter Arkh, 62:62-63, 1990.
Gala. R.R., Proc. Soc. Exp. Biol. Med. 198:513-27, 1991.
Gutierrez, M.A., Rev. Rhum. Fr. Ed., 1994, 61:278-85.
Hedner et al., Am. J. Ophthalmology, Oct. 1985, 618-19, vol. 100.
Holaday, J.W., "Neuroendocrine--Immune Interaction", 1991, 69 (Suppl. XXVI): 13-19, Klin Wochenschr.
Jara et al., Ame. J. of the Med. Sci., 303:222-226, Apr. 1992.
Jara et al., Semin, Arthritis Rheum., 5:273-284, 1991, vol. 20.
Kukhtevich et al., The Genuine Article, abstract No. FX734, Terapevtichdki Ardhiv, 63:99-101, 1991.
Lissoni et al., Eur J. Cancer, 30:167-170, 1994.
Lissoni et al., Oncology, 51:344-347, 1994.
Lissoni et al., Oncology, 52:163-166, 1995.
Lopez-Korpovitch et al., AJRI, 1994, 31:32-39, Jan.
Mattsson et al. Clin. Exp. Immunol., 85:41-47., 1991.
McMurray, R. et al., J. Immunol. 147:3780-7, 1991.
Meier et al., Experientia 48, 148-153, 1992.
Neri et al., Cancer, 73:3015-3019, 1994, Jun.
Nicoletti, I. et al., J. Reprod. Immunol., 15:113-121, 1989.
Parraques et al., J. Dev. Physiol. (1991) 16(2): 57-62.
Reder, A.T. and Lowry, M.T., J. Neurological Sci., 117:192-196, 1992.
Reber, P.M., Am J. Med., 1993 95 (6):637-644.
Regelson et al., Cancer Investigation, 5:379-385, 1987.
Reichlin, S., NEJM 329: 1246-53, 1993, Oct.
Rovensky, J. et al., Int. J. Immunopharmac., 13:267-272, 1991.
Vidaller, A. et al.,, Clin. Immunol. Immunopathol, 38:337-43, 1986.
Vidaller, A. et al., J. Clin. Immunol., 12:210-5, 1992.
Cincotta Anthony H.
Meier Albert H.
Agricultural and Mechanical College
Geist Gary
Keys Rosalynd
The General Hospital Corporation/Board of Supervisors of Louisia
LandOfFree
Method of regulating immune function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of regulating immune function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of regulating immune function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2062717